Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies

Ja Hye Myung, Khyati A. Gajjar, Jihua Chen, Robert E. Molokie, Seungpyo Hong

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Effective quantification and in situ identification of circulating tumor cells (CTCs) in blood are still elusive because of the extreme rarity and heterogeneity of the cells. In our previous studies, we developed a novel platform that captures tumor cells at significantly improved efficiency in vitro using a unique biomimetic combination of two physiological processes: E-selectin-induced cell rolling and poly(amidoamine) (PAMAM) dendrimer-mediated strong multivalent binding. Herein, we have engineered a novel multifunctional surface, on the basis of the biomimetic cell capture, through optimized incorporation of multiple antibodies directed to cancer cell-specific surface markers, such as epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor-2 (HER-2), and prostate specific antigen (PSA). The surfaces were tested using a series of tumor cells, MDA-PCa-2b, MCF-7, and MDA-MB-361, both in mixture in vitro and after being spiked into human blood. Our multifunctional surface demonstrated highly efficient capture of tumor cells in human blood, achieving up to 82% capture efficiency (∼10-fold enhancement than a surface with the antibodies alone) and up to 90% purity. Furthermore, the multipatterned antibodies allowed differential capturing of the tumor cells. These results support that our multifunctional surface has great potential as an effective platform that accommodates virtually any antibodies, which will likely lead to clinically significant, differential detection of CTCs that are rare and highly heterogeneous.

Original languageEnglish
Pages (from-to)6088-6094
Number of pages7
JournalAnalytical Chemistry
Volume86
Issue number12
DOIs
Publication statusPublished - 2014 Jun 17

Fingerprint

Tumors
Cells
Antibodies
Blood
Biomimetics
E-Selectin
Cell Adhesion Molecules
Prostate-Specific Antigen

All Science Journal Classification (ASJC) codes

  • Analytical Chemistry

Cite this

Myung, Ja Hye ; Gajjar, Khyati A. ; Chen, Jihua ; Molokie, Robert E. ; Hong, Seungpyo. / Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies. In: Analytical Chemistry. 2014 ; Vol. 86, No. 12. pp. 6088-6094.
@article{3f9a57a3b37247b8b07ffe7fbfd14327,
title = "Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies",
abstract = "Effective quantification and in situ identification of circulating tumor cells (CTCs) in blood are still elusive because of the extreme rarity and heterogeneity of the cells. In our previous studies, we developed a novel platform that captures tumor cells at significantly improved efficiency in vitro using a unique biomimetic combination of two physiological processes: E-selectin-induced cell rolling and poly(amidoamine) (PAMAM) dendrimer-mediated strong multivalent binding. Herein, we have engineered a novel multifunctional surface, on the basis of the biomimetic cell capture, through optimized incorporation of multiple antibodies directed to cancer cell-specific surface markers, such as epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor-2 (HER-2), and prostate specific antigen (PSA). The surfaces were tested using a series of tumor cells, MDA-PCa-2b, MCF-7, and MDA-MB-361, both in mixture in vitro and after being spiked into human blood. Our multifunctional surface demonstrated highly efficient capture of tumor cells in human blood, achieving up to 82{\%} capture efficiency (∼10-fold enhancement than a surface with the antibodies alone) and up to 90{\%} purity. Furthermore, the multipatterned antibodies allowed differential capturing of the tumor cells. These results support that our multifunctional surface has great potential as an effective platform that accommodates virtually any antibodies, which will likely lead to clinically significant, differential detection of CTCs that are rare and highly heterogeneous.",
author = "Myung, {Ja Hye} and Gajjar, {Khyati A.} and Jihua Chen and Molokie, {Robert E.} and Seungpyo Hong",
year = "2014",
month = "6",
day = "17",
doi = "10.1021/ac501243a",
language = "English",
volume = "86",
pages = "6088--6094",
journal = "Analytical Chemistry",
issn = "0003-2700",
publisher = "American Chemical Society",
number = "12",

}

Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies. / Myung, Ja Hye; Gajjar, Khyati A.; Chen, Jihua; Molokie, Robert E.; Hong, Seungpyo.

In: Analytical Chemistry, Vol. 86, No. 12, 17.06.2014, p. 6088-6094.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential detection of tumor cells using a combination of cell rolling, multivalent binding, and multiple antibodies

AU - Myung, Ja Hye

AU - Gajjar, Khyati A.

AU - Chen, Jihua

AU - Molokie, Robert E.

AU - Hong, Seungpyo

PY - 2014/6/17

Y1 - 2014/6/17

N2 - Effective quantification and in situ identification of circulating tumor cells (CTCs) in blood are still elusive because of the extreme rarity and heterogeneity of the cells. In our previous studies, we developed a novel platform that captures tumor cells at significantly improved efficiency in vitro using a unique biomimetic combination of two physiological processes: E-selectin-induced cell rolling and poly(amidoamine) (PAMAM) dendrimer-mediated strong multivalent binding. Herein, we have engineered a novel multifunctional surface, on the basis of the biomimetic cell capture, through optimized incorporation of multiple antibodies directed to cancer cell-specific surface markers, such as epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor-2 (HER-2), and prostate specific antigen (PSA). The surfaces were tested using a series of tumor cells, MDA-PCa-2b, MCF-7, and MDA-MB-361, both in mixture in vitro and after being spiked into human blood. Our multifunctional surface demonstrated highly efficient capture of tumor cells in human blood, achieving up to 82% capture efficiency (∼10-fold enhancement than a surface with the antibodies alone) and up to 90% purity. Furthermore, the multipatterned antibodies allowed differential capturing of the tumor cells. These results support that our multifunctional surface has great potential as an effective platform that accommodates virtually any antibodies, which will likely lead to clinically significant, differential detection of CTCs that are rare and highly heterogeneous.

AB - Effective quantification and in situ identification of circulating tumor cells (CTCs) in blood are still elusive because of the extreme rarity and heterogeneity of the cells. In our previous studies, we developed a novel platform that captures tumor cells at significantly improved efficiency in vitro using a unique biomimetic combination of two physiological processes: E-selectin-induced cell rolling and poly(amidoamine) (PAMAM) dendrimer-mediated strong multivalent binding. Herein, we have engineered a novel multifunctional surface, on the basis of the biomimetic cell capture, through optimized incorporation of multiple antibodies directed to cancer cell-specific surface markers, such as epithelial cell adhesion molecule (EpCAM), human epidermal growth factor receptor-2 (HER-2), and prostate specific antigen (PSA). The surfaces were tested using a series of tumor cells, MDA-PCa-2b, MCF-7, and MDA-MB-361, both in mixture in vitro and after being spiked into human blood. Our multifunctional surface demonstrated highly efficient capture of tumor cells in human blood, achieving up to 82% capture efficiency (∼10-fold enhancement than a surface with the antibodies alone) and up to 90% purity. Furthermore, the multipatterned antibodies allowed differential capturing of the tumor cells. These results support that our multifunctional surface has great potential as an effective platform that accommodates virtually any antibodies, which will likely lead to clinically significant, differential detection of CTCs that are rare and highly heterogeneous.

UR - http://www.scopus.com/inward/record.url?scp=84902805112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902805112&partnerID=8YFLogxK

U2 - 10.1021/ac501243a

DO - 10.1021/ac501243a

M3 - Article

C2 - 24892731

AN - SCOPUS:84902805112

VL - 86

SP - 6088

EP - 6094

JO - Analytical Chemistry

JF - Analytical Chemistry

SN - 0003-2700

IS - 12

ER -